FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979776614> ?p ?o ?g. }

• W2979776614 abstract "Abstract Background: The proto-oncogene Myc is a key regulator of cell growth and survival, and aberrant Myc expression plays a significant role in various tumors, including non-Hodgkin lymphoma (NHL). Myc-associated lymphoma is clinically aggressive, more resistant to standard therapies, and associated with a significantly higher rate of mortality. Novel treatment paradigms are needed to improve survival of patients with Myc-associated NHL. Expression of Aurora Kinase (Aurk) has been associated with Myc, and Aurk is thought to be essential for the maintenance of Myc-driven lymphoma. Aurk is required for assembly of the mitotic spindle and plays key roles in cell proliferation. Amplification and overexpression of Aurk have been observed in various human tumors, including lymphoma, and are frequently associated with tumor progression as well as resistance to chemotherapy. Inhibition of Aurk may overcome resistance to chemotherapy and improve clinical outcomes in patients with Myc-overexpressing lymphoma. Methods: Cytotoxicity assays using MTS and trypan blue were used to compare levels of drug sensitivity in lymphoma cell lines resistant or sensitive to a conventional chemotherapeutic drug cyclophosphamide. Apoptosis and cell cycle assays were performed using Annexin V and Propidium Iodide staining. The Multiplexed Inhibitor Beads and quantitative Mass Spectrometry (MIB/MS) assays were used to profile kinome changes in response to Aurk inhibition. Murine xenograft models were used to assess the efficacy and tolerability of single vs. combined therapy. Results: Two Myc-overexpressing cell lines were identified as resistant (Raji) or sensitive (Ramos) to cyclophosphamide, with IC50 of ~ 400 µM and ~ 250 µM, respectively. Raji cells were characterized by increased expression of multidrug resistant protein 1 (MDR1) and mutated p53. There were no significant differences in baseline Aurk or Myc expressions between Raji and Ramos cells. Both cell lines were sensitive to alisertib, an aurora A kinase inhibitor, with maximum cytotoxicity achieved at ~ 100 nM. Combined treatment with alisertib and cyclophosphamide induced more significant cell growth inhibition as compared to treatment with the single agent alone. The combination index (CI) values were less than 1, indicating that alisertib was synergistic to cyclophosphamide in terms of inhibitory effect on tumor cell viability. Alisertib induced apoptosis and pronounced cell cycle arrest, resulting in polyploidy, in Raji cells. Alisertib had little to no effect on Myc, p53, or the total aurora A kinase protein expression in Raji cells although p-Histone-3-Ser10, a downstream target of Aurk, and p-Src levels were significantly decreased at 24 hours of treatment in vitro. Nocodazole-treated cells had reduced p-Aurk level and increased p-Rb as well as increased Mdm2 when treated with alisertib for 24 hours. Athymic nude mice bearing Ramos or Raji lymphoma xenografts were treated with cyclophosphamide, alisertib, or the combination. As expected, all mice bearing Ramos xenograft had complete tumor regression by day 35 of treatment while all mice bearing Raji xenograft had rapid disease progression with median survival of ~ 35 days when treated with cyclophosphamide alone. In contrast, when treated with the combination of cyclophosphamide and alisertib, all mice bearing Raji xenograft had complete regression of tumor by day 35 and had significant improvement in survival (median survival not reached by day 100) compared to the single agent control (p=0.022). Lastly, kinome analysis of Raji xenograft tumors treated with alisertib showed suppression of various kinases involved in Aurk, Src, and PI3K pathways. Western blot of the Raji tumors treated with a prolonged course (25 days) of alisertib showed significant decrease in p-Src and p53 protein levels. Conclusion: Our data demonstrates that alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing tumors even in the presence of MDR1 overexpression and p53 mutation. The synergistic effect was largely independent of depletion of cytoplasmic level of Myc. Alisertib, when combined with a conventional chemotherapy drug, induced apoptosis and cell cycle arrest of Myc-overexpressing tumor cells in vitro and showed promising anti-tumor activity in mice bearing chemoresistant Myc-overexpressing lymphoma. Disclosures Park: Janssen: Other: travel; Seattle Genetics: Research Funding; Teva: Research Funding." @default.
• W2979776614 created "2019-10-18" @default.
• W2979776614 creator A5007260460 @default.
• W2979776614 creator A5011986576 @default.
• W2979776614 creator A5015840937 @default.
• W2979776614 creator A5016368300 @default.
• W2979776614 creator A5021245679 @default.
• W2979776614 creator A5031776733 @default.
• W2979776614 creator A5040843582 @default.
• W2979776614 creator A5048715563 @default.
• W2979776614 creator A5067366916 @default.
• W2979776614 creator A5076277214 @default.
• W2979776614 date "2015-12-03" @default.
• W2979776614 modified "2023-09-27" @default.
• W2979776614 title "Alisertib, an Aurora a Kinase Inhibitor, Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma Cells" @default.
• W2979776614 doi "https://doi.org/10.1182/blood.v126.23.1551.1551" @default.
• W2979776614 hasPublicationYear "2015" @default.
• W2979776614 type Work @default.
• W2979776614 sameAs 2979776614 @default.
• W2979776614 citedByCount "0" @default.
• W2979776614 crossrefType "journal-article" @default.
• W2979776614 hasAuthorship W2979776614A5007260460 @default.
• W2979776614 hasAuthorship W2979776614A5011986576 @default.
• W2979776614 hasAuthorship W2979776614A5015840937 @default.
• W2979776614 hasAuthorship W2979776614A5016368300 @default.
• W2979776614 hasAuthorship W2979776614A5021245679 @default.
• W2979776614 hasAuthorship W2979776614A5031776733 @default.
• W2979776614 hasAuthorship W2979776614A5040843582 @default.
• W2979776614 hasAuthorship W2979776614A5048715563 @default.
• W2979776614 hasAuthorship W2979776614A5067366916 @default.
• W2979776614 hasAuthorship W2979776614A5076277214 @default.
• W2979776614 hasConcept C16232356 @default.
• W2979776614 hasConcept C190283241 @default.
• W2979776614 hasConcept C203014093 @default.
• W2979776614 hasConcept C2775934118 @default.
• W2979776614 hasConcept C2777525834 @default.
• W2979776614 hasConcept C2779338263 @default.
• W2979776614 hasConcept C31573885 @default.
• W2979776614 hasConcept C502942594 @default.
• W2979776614 hasConcept C55493867 @default.
• W2979776614 hasConcept C71924100 @default.
• W2979776614 hasConcept C86803240 @default.
• W2979776614 hasConceptScore W2979776614C16232356 @default.
• W2979776614 hasConceptScore W2979776614C190283241 @default.
• W2979776614 hasConceptScore W2979776614C203014093 @default.
• W2979776614 hasConceptScore W2979776614C2775934118 @default.
• W2979776614 hasConceptScore W2979776614C2777525834 @default.
• W2979776614 hasConceptScore W2979776614C2779338263 @default.
• W2979776614 hasConceptScore W2979776614C31573885 @default.
• W2979776614 hasConceptScore W2979776614C502942594 @default.
• W2979776614 hasConceptScore W2979776614C55493867 @default.
• W2979776614 hasConceptScore W2979776614C71924100 @default.
• W2979776614 hasConceptScore W2979776614C86803240 @default.
• W2979776614 hasLocation W29797766141 @default.
• W2979776614 hasOpenAccess W2979776614 @default.
• W2979776614 hasPrimaryLocation W29797766141 @default.
• W2979776614 hasRelatedWork W1945485651 @default.
• W2979776614 hasRelatedWork W1981710542 @default.
• W2979776614 hasRelatedWork W1985784564 @default.
• W2979776614 hasRelatedWork W2077212219 @default.
• W2979776614 hasRelatedWork W2126572395 @default.
• W2979776614 hasRelatedWork W2428743865 @default.
• W2979776614 hasRelatedWork W2529740077 @default.
• W2979776614 hasRelatedWork W2554542387 @default.
• W2979776614 hasRelatedWork W2563757607 @default.
• W2979776614 hasRelatedWork W2569374499 @default.
• W2979776614 hasRelatedWork W2582169812 @default.
• W2979776614 hasRelatedWork W2586123530 @default.
• W2979776614 hasRelatedWork W2588565580 @default.
• W2979776614 hasRelatedWork W2605413314 @default.
• W2979776614 hasRelatedWork W2618389973 @default.
• W2979776614 hasRelatedWork W2753386331 @default.
• W2979776614 hasRelatedWork W2979551512 @default.
• W2979776614 hasRelatedWork W2981042109 @default.
• W2979776614 hasRelatedWork W2989206149 @default.
• W2979776614 hasRelatedWork W348581781 @default.
• W2979776614 isParatext "false" @default.
• W2979776614 isRetracted "false" @default.
• W2979776614 magId "2979776614" @default.
• W2979776614 workType "article" @default.